Cytodyn, Inc.
Clinical trials sponsored by Cytodyn, Inc., explained in plain language.
-
HIV drug extension study halted early: what happened?
Disease control TerminatedThis study looked at whether weekly injections of PRO 140, taken with standard HIV medications, could keep the virus under control over the long term. It enrolled 43 people who had already completed an earlier PRO 140 study and had undetectable virus levels. The study was termina…
Phase: PHASE2, PHASE3 • Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
HIV patients test weekly shots to replace daily pills
Disease control TerminatedThis study tested whether HIV patients who already had the virus under control could switch to weekly injections of leronlimab (PRO 140) instead of their usual daily pills. The goal was to see if the drug alone could keep the virus suppressed safely over a longer period. The tria…
Phase: PHASE2, PHASE3 • Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
HIV Antibody-Only therapy falls short in Long-Term trial
Disease control TerminatedThis study tested whether a single antibody called PRO 140 could keep HIV under control in 20 adults who had been stable on standard combination therapy. Participants stopped their usual HIV pills and received only PRO 140 infusions. The trial was stopped early, and the main goal…
Phase: PHASE2 • Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Promising combo for Triple-Negative breast cancer stalls as trial ends early
Disease control TerminatedThis early-phase trial tested a drug called leronlimab combined with the chemotherapy carboplatin in people with a specific type of advanced triple-negative breast cancer (CCR5-positive). The goal was to find a safe dose and see if it could slow cancer growth. However, the study …
Phase: PHASE1, PHASE2 • Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated Jun 26, 2026 15:01 UTC